Jackson Center, PA, December 1, 2020 – Halberd Corp. (OTC PINK: "HALB") announces the reorganization of its Scientific Advisory Board. The new Advisory Board will consist of two sub-boards: a multi-disciplined Scientific Advisory Board focused on biomedical issues and a Business Advisory Board focusing on business issues. The two boards will interface on a regular ...
Jackson Center, PA, November 25, 2020 – Halberd Corporation (OTC-PINK: "HALB") Chairman, President and CEO, William A. Hartman, was interviewed this week by host, Donald Baillargeon, on Money TV. Mr. Hartman recapped the company’s accomplishments, describing its most promising technologies and described the unique applications perceived, including a sneak peek at the future. Mr. Hartman ...
Jackson Center, PA, November 19, 2020 – Halberd Corp. (OTC PINK: "HALB") reported the filing of a provisional patent application on a variation of Halberd’s patented extracorporeal method to treat/eradicate Covid-19 from a patient’s blood. By using an extracorporeal (outside the body) treatment method, the patient is exposed to far fewer potential negative side effects ...
Mr. Hartman discusses advantages over existing antibodies. Jackson Center, PA, November 16, 2020 – Halberd Corporation (OTC-PINK: "HALB") Chairman, President and CEO, William A. Hartman, was interviewed recently by host, Donald Baillargeon, on Money TV. In the segment, Mr. Hartman provided information on Halberd’s new patent pending Covid-19 fluorescent antibody. This should allow for rapid ...
Jackson Center, PA, November 12, 2020 – Halberd Corporation (OTC PINK: "HALB") today disclosed information on their patent-pending fluorescent anti-Spike protein monoclonal antibodies against Covid-19 developed in conjunction with Dr. Qiang (Shawn) Chen of Arizona State University. The salient feature of Halberd’s new class of antibody is that it fluoresces in the presence of Covid-19 ...
Jackson Center, PA, November 9, 2020 – Halberd Corp. (OTC PINK: "HALB") reported the filing of a Covid-19 provisional patent on an enhanced nasal spray. The application, “Nasal Spray to Prevent the Transmission of Covid-19,” discloses a combination of proprietary Covid-19 Spike Protein antibodies, ACE2 antibody, and Neuropilin-1 antibodies. This application builds on, and is ...
Jackson Center, PA, November 5, 2020 – Halberd Corporation (OTC PINK: "HALB") reports its research team developed a second monoclonal antibody against Covid-19 SARS 2 disease antigens paving the way for development of a potentially more effective nasal spray. Additionally, Halberd’s continuing work on its new class of antibody doubles the performance capacity of a ...
In Case You Missed It - Mr. Hartman discusses recent accomplishments and new opportunities. Jackson Center, PA, November 2, 2020 – Halberd Corporation (OTC-PINK: "HALB") Chairman, President and CEO, William A. Hartman, was interviewed recently by host, Donald Baillargeon, on Money TV. In the segment, Mr. Hartman provided an update on the company’s latest activities, ...
Jackson Center, PA, October 29, 2020 – Halberd Corporation (OTC PINK: "HALB") today provided insight concerning its strategic plans beyond developing unique antibodies which form the basis of their current all-out efforts to generate products and processes to prevent, diagnose and treat Covid-19. These strategic plans are designed to benefit people well after Covid-19 is ...
Jackson Center, PA, October 27, 2020 – Halberd Corporation (OTC PINK: "HALB") has retained the services of a prestigious Pittsburgh, PA law firm, Ference & Associates, to handle its intellectual property matters. The initial application focuses on patenting Halberd’s base Covid-19 antibody as well as an entire new class of antibody conjugate. The primary attorney ...